NEXT CRO is a highly added value, Contract Research Organisation (CRO), running Clinical Trials in Greece, Turkey and Cyprus, and with its alliances, globally, offering “plug and play” Study Teams.

WHY CHOOSE NEXT CRO

  • With NEXT CRO, you can check-in to our alliances and receive Clinical Trial Services, globally
  • With NEXT CRO, you receive Local Expertise which leads to fast approvals, best selection of Investigators and high recruitments
  • NEXT CRO offers an experienced Management Team, that successfully oversees the experienced Study Teams - Therefore, achieving their study goals
  • NEXT CRO provides added value expertise in all therapeutic areas, including rare diseases
  • NEXT CRO provides flexibility, high efficiency, being a fully ethical company
  • NEXT CRO provides healthy Finances being a financially stable, privately owned CRO with a backlog exceeding 1.5 times the yearly turnover

WITH NEXT CRO, YOU HAVE DIRECT ACCESS
TO THE REGION OF GREECE, TURKEY AND CYPRUS

THE REGION IS FULLY REGULATED FOLLOWING THE EC REGULATIONS AND STANDARDS

Clinical Trials conducted in emerging regions have expanded to include more countries. Among these newly emerging countries, Greece, Turkey and Cyprus have shown exponential growth in foreign-sponsored Clinical Trials. Greece and Cyprus are EU member and part of Eurozone. Turkey has a geographic proximity to Europe. Greece and Turkey show successful patient recruitment rates, presence of highly skilled Investigators and reduced Clinical Trial costs. Greece, Turkey and Cyprus have in total a population of more than 90 million people offering high recruitment potential. Most clinical sites in Greece and Turkey are in Universities and specialized hospitals in the big cities. These institutions offer access to a large pool of eligible subjects which greatly facilitates patient recruitment.

Clinical Trials in Greece and Turkey are conducted in several therapeutic areas, including a number of rare diseases as well as diseases formerly prevalent in more developed countries including cardiovascular diseases, diabetes, obesity, hypercholesterolemia, and several types of cancer. Population growth, increased life expectancy, urbanization, tobacco consumption, and the adoption of western dietary habits have all contributed to an increasing prevalence of these diseases in the region.

The current economic situation has a significant impact to the Healthcare status of these Countries. Therefore, Clinical Trials are more than welcome in this region by patients’ communities, National Health System Institutions, Hospitals and Medical Doctors. Besides, Clinical Trials are considered as a source of income and inflow for the National Health Systems of the region.